Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Real-time Estimate Cboe BZX
Other stock markets
 09:42:40 2024-04-18 am EDT 		5-day change 1st Jan Change
47.72 USD -0.25% Intraday chart for Bristol-Myers Squibb Company -4.87% -6.76%
11:59am Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Apr. 17 TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation
  • The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The group's high margin levels account for strong profits.
  • The company has a low valuation given the cash flows generated by its activity.
  • The company is one of the best yield companies with high dividend expectations.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The group shows a rather high level of debt in proportion to its EBITDA.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
BRISTOL-MYERS SQUIBB COMPANY Stock Bristol-Myers Squibb Company
-6.76% 96.96B
B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+28.79% 676B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+23.82% 554B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.64% 349B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.00% 318B
B-
ABBVIE INC. Stock AbbVie Inc.
+5.99% 291B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+2.55% 210B
B+
NOVARTIS AG Stock Novartis AG
-0.45% 204B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.94% 194B
A+
PFIZER, INC. Stock Pfizer, Inc.
-11.71% 144B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Ratings Bristol-Myers Squibb Company